Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Up 1.3%

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares rose 1.3% on Wednesday . The stock traded as high as $88.12 and last traded at $87.23. Approximately 327 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 2,689 shares. The stock had previously closed at $86.08.

Wall Street Analysts Forecast Growth

Separately, BTIG Research started coverage on Zealand Pharma A/S in a research report on Thursday, March 7th. They set a “buy” rating for the company.

Zealand Pharma A/S Price Performance

The company’s 50-day simple moving average is $91.99 and its 200-day simple moving average is $66.60. The company has a market cap of $4.49 billion, a price-to-earnings ratio of -47.93 and a beta of 0.63.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.08). The firm had revenue of $3.35 million for the quarter, compared to analysts’ expectations of $1.97 million. Zealand Pharma A/S had a negative return on equity of 49.78% and a negative net margin of 203.99%. Equities analysts predict that Zealand Pharma A/S will post -2.56 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.